Literature DB >> 23334809

Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening.

V S Nunes1, G L Souza, D Perone, S J Conde, C R Nogueira.   

Abstract

The purpose of this study it was to evaluate the frequency of Multiple Endocrine Neoplasia type 1 (MEN1) in patients with pituitary adenoma and to perform genetic analysis and familial screening of those individuals afflicted with MEN1. 144 patients with pituitary adenoma at Botucatu Medical School, UNESP-Univ Estadual Paulista, were assessed retrospectively for MEN1 during the years of 2005-2011. The patients were evaluated for the presence of primary hyperparathyroidism (PHP) and enteropancreatic tumors. Genetic analysis was performed for the individuals with clinically diagnosed MEN1. Thirteen patients met the diagnostic criteria for MEN1, but three individuals belong to the same family and they were considered as a single MEN1 event, revealing 7.7 % frequency of MEN1 in this patient group. Genetic analysis showed MEN1 mutations in four index cases: IVS4+1 G>A, IVS3-6 C>T, c.1547insC and a new D180A mutation. One patient did not agree to participate in the genetic study and another one was referred for follow up in other hospital. Only polymorphisms were found in the other individuals, one of which was novel. We identified a high frequency of MEN1 in pituitary adenoma patients. Since PHP is one of the most common MEN1 tumor and patients are mostly asymptomatic, we suggest that all pituitary adenoma patients have their calcium profile analyzed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23334809     DOI: 10.1007/s11102-013-0462-8

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  30 in total

Review 1.  [Genetic polymorphisms: implications in the pathogenesis of medullary thyroid carcinoma].

Authors:  Andreia Possatti da Rocha; Patrícia K Ribeiro Magalhães; Ana Luiza Maia; Lea Maria Zanini Maciel
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-07

2.  Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing.

Authors:  S Ellard; A T Hattersley; C M Brewer; B Vaidya
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

Review 3.  Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations.

Authors:  K Oberg; B Skogseid; B Eriksson
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

Review 4.  Multiple endocrine neoplasia type 1.

Authors:  R V Thakker
Journal:  Endocrinol Metab Clin North Am       Date:  2000-09       Impact factor: 4.741

5.  Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study.

Authors:  Bruno Vergès; Françoise Boureille; Pierre Goudet; Arnaud Murat; Albert Beckers; Geneviève Sassolas; Patrick Cougard; Béatrice Chambe; Corinne Montvernay; Alain Calender
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

6.  The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.

Authors:  Chrysanthia A Leontiou; Maria Gueorguiev; Jacqueline van der Spuy; Richard Quinton; Francesca Lolli; Sevda Hassan; Harvinder S Chahal; Susana C Igreja; Suzanne Jordan; Janice Rowe; Marie Stolbrink; Helen C Christian; Jessica Wray; David Bishop-Bailey; Dan M Berney; John A H Wass; Vera Popovic; Antônio Ribeiro-Oliveira; Monica R Gadelha; John P Monson; Scott A Akker; Julian R E Davis; Richard N Clayton; Katsuhiko Yoshimoto; Takeo Iwata; Akira Matsuno; Kuniki Eguchi; Mâdâlina Musat; Daniel Flanagan; Gordon Peters; Graeme B Bolger; J Paul Chapple; Lawrence A Frohman; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

7.  Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1.

Authors:  L Benson; S Ljunghall; G Akerström; K Oberg
Journal:  Am J Med       Date:  1987-04       Impact factor: 4.965

Review 8.  Multiple endocrine neoplasia type 1. Clinical features and screening.

Authors:  B Skogseid; J Rastad; K Oberg
Journal:  Endocrinol Metab Clin North Am       Date:  1994-03       Impact factor: 4.741

9.  Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.

Authors:  Jacqueline Trouillas; Françoise Labat-Moleur; Nathalie Sturm; Michèle Kujas; Marie-Françoise Heymann; Dominique Figarella-Branger; Martine Patey; Marc Mazucca; Evelyne Decullier; Bruno Vergès; Olivier Chabre; Alain Calender
Journal:  Am J Surg Pathol       Date:  2008-04       Impact factor: 6.394

10.  Pituitary adenomas of the multiple endocrine neoplasia type I syndrome.

Authors:  B W Scheithauer; E R Laws; K Kovacs; E Horvath; R V Randall; J A Carney
Journal:  Semin Diagn Pathol       Date:  1987-08       Impact factor: 3.464

View more
  4 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

2.  Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic.

Authors:  N V Marques; L Kasuki; M C Coelho; C H A Lima; L E Wildemberg; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2017-07-08       Impact factor: 4.256

Review 3.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

4.  Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly.

Authors:  Lisa B Nachtigall; Francisco J Guarda; Kate E Lines; Alireza Ghajar; Laura Dichtel; Giselle Mumbach; Wenxiu Zhao; Xun Zhang; Nicholas A Tritos; Brooke Swearingen; Karen K Miller; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.